Research map: Modeling the public health impact of vaccination with Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025–2026 formula in the pediatric population aged 5–17 years at high risk of severe outcomes from COVID-19 in the United States

Back to the article

Papers in this map

  1. Risk Factors Associated With Post−COVID-19 Condition · Vasiliki Tsampasian · 2023 · 840 citations · Cited by this paper
  2. Epidemiological characteristics of varicella and factors associated with breakthrough varicella among children aged 0–14 years in Jiangsu Province, China · 2026 · Related
  3. Model Transparency and Validation · David M. Eddy · 2012 · 818 citations · Cited by this paper
  4. Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit–cost analysis · 2026 · Related
  5. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1–July 25, 2020 · Lindsay Kim · 2020 · 533 citations · Cited by this paper
  6. Progress toward an Epstein-Barr virus vaccine · 2026 · Related
  7. A systematic review of factors affecting vaccine uptake in young children · Louise E. Smith · 2017 · 484 citations · Cited by this paper
  8. Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit–cost analysis · 2026 · Related
  9. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine · Tom T. Shimabukuro · 2021 · 335 citations · Cited by this paper
  10. Pneumococcal conjugate vaccines in older adults and immunocompromised individuals · 2025 · Related
  11. COVID-19 will continue but the end of the pandemic is near · Christopher J L Murray · 2022 · 234 citations · Cited by this paper
  12. Healthcare professionals’ perspectives and preferences regarding adolescent meningococcal disease vaccination in the United States · 2026 · Related
  13. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents · Samantha M. Olson · 2022 · 200 citations · Cited by this paper
  14. Whole cell and acellular pertussis vaccines - rethinking the evidence · 2026 · Related
  15. Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection · Anna Louise Funk · 2022 · 118 citations · Cited by this paper
  16. The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study · 2026 · Related
  17. Rate of SARS-CoV-2 Reinfection During an Omicron Wave in Iceland · Elías Sæbjörn Eyþórsson · 2022 · 98 citations · Cited by this paper
  18. Prevalence and Trends in Pediatric-Onset Chronic Conditions in the United States, 1999-2018 · Lauren E. Wisk · 2025 · 67 citations · Cited by this paper
  19. Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges · Thirumalaisamy Palanichamy Velavan · 2023 · 51 citations · Cited by this paper
  20. Spatial distribution dynamics and prediction of COVID‐19 in Asian countries: spatial Markov chain approach · Zahra Dehghan Shabani · 2020 · 50 citations · Cited by this paper
  21. Prevalence of Symptoms ≤12 Months After Acute Illness, by COVID-19 Testing Status Among Adults — United States, December 2020–March 2023 · Juan Carlos C. Montoy · 2023 · 49 citations · Cited by this paper
  22. A Continuous Markov-Chain Model for the Simulation of COVID-19 Epidemic Dynamics · Zhaobin Xu · 2022 · 47 citations · Cited by this paper
  23. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States · Manuela Di Fusco · 2022 · 42 citations · Cited by this paper
  24. An assessment of parental knowledge, attitudes, and beliefs regarding influenza vaccination · Maureen D. Goss · 2019 · 40 citations · Cited by this paper
  25. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years · Leora R. Feldstein · 2024 · 36 citations · Cited by this paper
  26. Reinfections with Different SARS-CoV-2 Omicron Subvariants, France · Nhu Ngoc Nguyen · 2022 · 29 citations · Cited by this paper
  27. Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents · Qiong Wu · 2024 · 26 citations · Cited by this paper
  28. Pediatric Vaccine Hesitancy in the United States—The Growing Problem and Strategies for Management Including Motivational Interviewing · Ashlesha Kaushik · 2025 · 23 citations · Cited by this paper
  29. COVID-19 Vaccination and Odds of Post–COVID-19 Condition Symptoms in Children Aged 5 to 17 Years · Anna R. Yousaf · 2025 · 22 citations · Cited by this paper
  30. Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations · Alessandra Løchen · 2021 · 20 citations · Cited by this paper
  31. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents · Nicola P. Klein · 2023 · 20 citations · Cited by this paper
  32. Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026 · Patrick Maloney · 2026 · 18 citations · Cited by this paper
  33. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States · Manuela Di Fusco · 2023 · 16 citations · Cited by this paper
  34. Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents — United States, 2021–2023 · Laura Divens Zambrano · 2024 · 16 citations · Cited by this paper
  35. Hospitalization for COVID-19 and Risk Factors for Severe Disease Among Children: 2022–2024 · Rebecca J. Free · 2025 · 14 citations · Cited by this paper
  36. Effectiveness of 2024–2025 COVID-19 Vaccines in Children in the United States — VISION, August 29, 2024–September 2, 2025 · Stephanie A. Irving · 2025 · 12 citations · Cited by this paper
  37. BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age · Sara Yee Tartof · 2024 · 12 citations · Cited by this paper
  38. Estimated Burden of COVID-19 Illnesses, Medical Visits, Hospitalizations, and Deaths in the US From October 2022 to September 2024 · Emilia H. A. Koumans · 2026 · 12 citations · Cited by this paper
  39. Health outcomes and economic burden among patients with a COVID-19-associated hospitalization in the United States during the predominance of the XBB and JN.1 omicron lineages · Alon Yehoshua · 2024 · 11 citations · Cited by this paper

Source: OpenAlex (CC0)